| __timestamp | Blueprint Medicines Corporation | Jazz Pharmaceuticals plc |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 406114000 |
| Thursday, January 1, 2015 | 14456000 | 449119000 |
| Friday, January 1, 2016 | 19218000 | 502892000 |
| Sunday, January 1, 2017 | 27986000 | 544156000 |
| Monday, January 1, 2018 | 47928000 | 683530000 |
| Tuesday, January 1, 2019 | 96388000 | 736942000 |
| Wednesday, January 1, 2020 | 157743000 | 854233000 |
| Friday, January 1, 2021 | 195293000 | 1451683000 |
| Saturday, January 1, 2022 | 237374000 | 1416967000 |
| Sunday, January 1, 2023 | 295141000 | 1343105000 |
| Monday, January 1, 2024 | 359272000 |
Unleashing the power of data
In the competitive landscape of biopharmaceuticals, understanding the financial strategies of leading companies is crucial. Jazz Pharmaceuticals plc and Blueprint Medicines Corporation, two prominent players, have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade.
From 2014 to 2023, Jazz Pharmaceuticals consistently outspent Blueprint Medicines, with SG&A expenses peaking at approximately 1.45 billion in 2021. This represents a staggering 250% increase from their 2014 figures. In contrast, Blueprint Medicines, while starting with a modest 7.89 million in 2014, saw a dramatic rise to nearly 295 million by 2023, marking an impressive 3,600% growth.
These trends highlight Jazz's established market presence and Blueprint's aggressive expansion strategy. As the biopharma sector evolves, monitoring these financial patterns offers valuable insights into each company's operational focus and market positioning.
Who Optimizes SG&A Costs Better? Johnson & Johnson or Jazz Pharmaceuticals plc
Sanofi or Jazz Pharmaceuticals plc: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Blueprint Medicines Corporation
Operational Costs Compared: SG&A Analysis of Neurocrine Biosciences, Inc. and Jazz Pharmaceuticals plc
Selling, General, and Administrative Costs: Summit Therapeutics Inc. vs Jazz Pharmaceuticals plc
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Celldex Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Axsome Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Alpine Immune Sciences, Inc.
Blueprint Medicines Corporation or Amneal Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Blueprint Medicines Corporation vs Ligand Pharmaceuticals Incorporated Trends and Insights
Cost Management Insights: SG&A Expenses for Blueprint Medicines Corporation and Dynavax Technologies Corporation